608 related articles for article (PubMed ID: 30665488)
21. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
22. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
Ribas A; Medina T; Kummar S; Amin A; Kalbasi A; Drabick JJ; Barve M; Daniels GA; Wong DJ; Schmidt EV; Candia AF; Coffman RL; Leung ACF; Janssen RS
Cancer Discov; 2018 Oct; 8(10):1250-1257. PubMed ID: 30154193
[TBL] [Abstract][Full Text] [Related]
23. Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma.
Domingo-Musibay E; Murugan P; Giubellino A; Sharma S; Steinberger D; Yuan J; Hunt MA; Lou E; Miller JS
J Immunother Cancer; 2018 Jun; 6(1):58. PubMed ID: 29914578
[TBL] [Abstract][Full Text] [Related]
24. The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.
Nguyen MC; Shah MH; Liebner DA; Backes FJ; Phay J; Shirley LA
J Natl Compr Canc Netw; 2018 Nov; 16(11):1279-1283. PubMed ID: 30442730
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
[TBL] [Abstract][Full Text] [Related]
26. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
27. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
28. No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.
Stoehr R; Wendler O; Giedl J; Gaisa NT; Richter G; Campean V; Burger M; Wullich B; Bertz S; Hartmann A
Pathobiology; 2019; 86(2-3):145-151. PubMed ID: 30650417
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
[TBL] [Abstract][Full Text] [Related]
30. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
31. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
Ben-Betzalel G; Steinberg-Silman Y; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2019 Feb; 108():61-68. PubMed ID: 30648631
[TBL] [Abstract][Full Text] [Related]
34. The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Garcia C; Ring KL
Curr Treat Options Oncol; 2018 Nov; 19(12):70. PubMed ID: 30397772
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age.
Chanal J; Kramkimel N; Ratour C; Aractingi S; Guégan S; Avril MF
Dermatology; 2019; 235(3):219-224. PubMed ID: 30721908
[TBL] [Abstract][Full Text] [Related]
36. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
Michalarea V; Fontana E; Garces AI; Williams A; Smyth EC; Picchia S; Rao S; Chau I; Cunningham D; Bali MA
Curr Probl Cancer; 2019 Oct; 43(5):487-494. PubMed ID: 30827742
[TBL] [Abstract][Full Text] [Related]
37. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of Colon Cancer.
Stein A; Folprecht G
Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
[TBL] [Abstract][Full Text] [Related]
39. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
40. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
